Cartesian Therapeutics, Inc. (RNAC)
7.00
+0.22
(+3.24%)
USD |
NASDAQ |
Nov 06, 10:25
Cartesian Therapeutics Net Income (Quarterly) : 13.72M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 13.72M |
| March 31, 2026 | -39.18M |
| December 31, 2025 | -92.58M |
| September 30, 2025 | -35.90M |
| June 30, 2025 | 15.89M |
| March 31, 2025 | -17.71M |
| September 30, 2024 | -24.18M |
| June 30, 2024 | 9.628M |
| March 31, 2024 | -56.82M |
| December 31, 2023 | -215.21M |
| September 30, 2023 | -9.002M |
| June 30, 2023 | -11.39M |
| March 31, 2023 | -21.66M |
| December 31, 2022 | 5.893M |
| September 30, 2022 | -7.893M |
| June 30, 2022 | 8.601M |
| March 31, 2022 | 28.78M |
| December 31, 2021 | 12.24M |
| September 30, 2021 | -17.89M |
| June 30, 2021 | 4.565M |
| March 31, 2021 | -24.60M |
| Date | Value |
|---|---|
| December 31, 2020 | -15.45M |
| September 30, 2020 | -9.729M |
| June 30, 2020 | -24.08M |
| March 31, 2020 | -19.62M |
| December 31, 2019 | -14.89M |
| September 30, 2019 | -11.99M |
| June 30, 2019 | -16.39M |
| March 31, 2019 | -12.07M |
| December 31, 2018 | -14.65M |
| September 30, 2018 | -16.00M |
| June 30, 2018 | -18.80M |
| March 31, 2018 | -15.89M |
| December 31, 2017 | -19.54M |
| September 30, 2017 | -14.68M |
| June 30, 2017 | -15.97M |
| March 31, 2017 | -15.13M |
| December 31, 2016 | -14.08M |
| September 30, 2016 | -7.728M |
| June 30, 2016 | -6.923M |
| March 31, 2016 | -7.476M |
| March 31, 2015 | -5.733M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | -13.72M |
| EPS Diluted (Quarterly) | 0.4595 |
| Enterprise Value | 119.90M |
| Earnings Yield | -84.85% |
| Normalized Earnings Yield | -57.95 |